Table 1

Consensus guidelines on immunomodulatory therapy in times of COVID-19 in increased risk patients* (n=139)

Healthy patientsHealthy patients with close contactSick patient: COVID-19 suspectedSick patient: COVID-19 positive
Oral corticosteroidsPt not on oral corticosteroidsTo be started123 (88.5%)44 (31.7%)7 (5%)8 (5.8%)
Pt on low-dose oral corticosteroidsTo be maintained132 (95.0%)112 (80.6%)57 (41.0%)38 (27.3%)
To be decreased11 (7.9%)51 (36.7%)92 (66.2%)104 (74.8%)
To be tapered and stopped13 (9.4%)38 (27.3%)83 (59.7%)98 (70.5%)
Pt on higher-dose oral corticosteroidsTo be maintained102 (73.4%)55 (39.6%)19 (13.7%)11 (7.9%)
To be decreased38 (27.3%)80 (57.6%)117 (84.2%)125 (89.9%)
To be tapered and stopped21 (15.1%)52 (37.4%)99 (71.2%)107 (77%)
Intravenous methyl prednisoloneTo consider103 (74.1%)32 (23%)6 (4.3%)5 (3.6%)
Local corticosteroidsPt not on oral corticosteroidsTo be preferred to systemic therapy83 (59.7%)118 (84.9%)128 (92.1%)122 (87.8%)
Pt on low-dose oral corticosteroidsTo be preferred to increasing the dose of systemic therapy106 (76.3%)121 (87.1%)126 (90.6%)122 (87.8%)
Conventional IMTTo be started104 (74.8%)38 (27.3%)3 (2.2%)1 (0.7%)
To be maintained135 (97.1%)95 (68.3%)26 (18.7%)13 (9.4%)
To be decreased9 (6.5%)51 (36.7%)113 (81.3%)123 (88.5%)
To be stopped5 (3.6%)32 (23%)107 (77%)122 (87.8%)
  • Consensus for ‘No’

  • Consensus for ‘Yes’

  • *Increased risk category: patients with uveitis or rheumatologic disease on immunosuppressives (not on biologics).

  • MT, immunosuppressive therapy; Pt, patients.